Aclaris Therapeutics (ACRS) News
NASDAQ: ACRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.44-0.06 (-1.71%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ACRS news summary
We found 16 recent headlines mentioning Aclaris Therapeutics (ACRS): 6 in the past week and 14 in the past 30 days, most often from Nasdaq, GlobeNewswire, Investing.com. For price context, ACRS is down 1.71% at $3.44. The most recent story, "Why is Aclaris Therapeutics stock sliding today?", was published by Investing.com on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Aclaris Therapeutics headlines
- Why is Aclaris Therapeutics stock sliding today?Investing.com
- Aclaris Launched Phase 2b Trial Of Modzatinib For Lichen Planus; Stock Down(RTTNews) - Aclaris Therapeutics, Inc. (ACRS) announced the initiation of a Phase 2b trial, dubbed ALPHA, evaluating modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus (LP), a…NasdaqACRS, ET
- Aclaris Therapeutics, Inc. Announces Phase 2 Trial Results for Bosakitug and Initiates Phase 2b ALPHA Trial of ModzatinibAclaris Therapeutics, Inc. announced top line results from its Phase 2 ADMIRATION trial of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin monoclonal antibody, in patients with…Nasdaq
- Aclaris Reports Bosakitug Phase 2 Setback, Focuses To Other Pipeline Programs(RTTNews) - Aclaris Therapeutics, Inc. (ACRS) reported top-line results from its Phase 2 ADMIRATION trial evaluating bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis,…NasdaqACRS, MKC.V
- Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)GlobeNewswire
- Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)GlobeNewswire
- Aclaris Therapeutics to Participate in the Jefferies Global Healthcare ConferenceAclaris Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswire
- Aclaris Therapeutics, Inc. Reports Third Quarter 2026 Financial ResultsAclaris Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026. The company reported a net loss of $18.5 million and total revenue of $1.5 million for the…Nasdaq
- Aclaris Therapeutics GAAP EPS of -$0.12 beats by $0.04, revenue of $1.48M beats by $0.25MSeeking Alpha
- Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical UpdateAclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical UpdateGlobeNewswire
- Aclaris Therapeutics, Inc. Enters Underwriting Agreement for Offering of 7,785,714 Shares of Common Stock and 6,500,000 Pre-Funded WarrantsOn October 27, 2026, Aclaris Therapeutics, Inc. entered into an underwriting agreement to issue and sell 7,785,714 shares of common stock of the Company, par value $0.00001 per share, and pre-funded…NasdaqACRS, BIO.B
- Aclaris Therapeutics, Inc. Announces Phase 1b Results for ATI-052 and Estimates $204.6 million in CashAclaris Therapeutics, Inc. announced primary analysis results from its Phase 1b proof-of-concept trials of ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, in patients with severe atopic…Nasdaq
- Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded WarrantsAclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and AsthmaAclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic DermatitisGlobeNewswire
- Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?Here is how Aclaris Therapeutics (ACRS) and Glaukos (GKOS) have performed compared to their sector so far this year.NasdaqACRS, GKOS
- After Hours Most Active for Jul 15, 2026 : PFE, T, ACRS, NVDA, KO, MSFT, WFC, VZ, ASTS, AUR, WBD, HDBThe NASDAQ 100 After Hours Indicator is up 2.05 to 29,504.65. The total After hours volume is currently 125,388,614 shares traded.The following are the most active stocks for the after hours session:…NasdaqPFE, T, ACRS, NVDA